Top Page
Jiangxi Rimag Group Co., Ltd. Class H
(2522)
Jiangxi Rimag Group Co., Ltd. Class H (2522) vs. iShares MSCI Hong Kong ETF (EWH)
Jiangxi Rimag Group Co., Ltd. Class H Business Overview & Revenue Model
Jiangxi Rimag Group Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 813.93M | 760.59M | 928.91M | 784.44M | 592.01M |
| Gross Profit | 254.92M | 277.33M | 332.60M | 236.95M | 175.19M |
| EBITDA | 139.79M | 169.30M | 256.20M | 207.86M | -147.44M |
| Net Income | -33.31M | -45.92M | 44.41M | 364.00K | -360.73M |
Balance Sheet | |||||
| Total Assets | 2.42B | 2.26B | 1.88B | 1.99B | 2.06B |
| Cash, Cash Equivalents and Short-Term Investments | 381.71M | 262.79M | 215.79M | 355.62M | 509.67M |
| Total Debt | 528.37M | 578.61M | 386.02M | 489.07M | 574.76M |
| Total Liabilities | 798.15M | 779.76M | 543.54M | 673.18M | 752.48M |
| Stockholders Equity | 1.59B | 1.46B | 1.29B | 1.27B | 1.27B |
Cash Flow | |||||
| Free Cash Flow | -71.40M | -298.75M | 104.92M | -73.46M | -124.68M |
| Operating Cash Flow | 71.64M | 12.74M | 201.44M | 198.17M | 18.00M |
| Investing Cash Flow | -215.73M | -327.05M | -117.07M | -251.54M | -151.03M |
| Financing Cash Flow | 199.17M | 383.74M | -235.72M | -96.45M | 452.92M |
Jiangxi Rimag Group Co., Ltd. Class H Technical Analysis
Jiangxi Rimag Group Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | HK$7.90B | 4.14 | 94.40% | ― | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | HK$72.49B | -56.11 | -48.85% | ― | ― | ― | |
48 Neutral | HK$17.58B | -35.50 | -11.44% | ― | ― | ― | |
44 Neutral | HK$3.31B | -80.94 | -2.15% | ― | ― | ― | |
44 Neutral | HK$29.80B | -34.10 | -7.40% | ― | 33.20% | 34.66% | |
40 Neutral | HK$1.96B | -6.31 | -12.63% | ― | ― | ― |
Jiangxi Rimag Group Co., Ltd. Class H Corporate Events
Jiangxi Rimag Group Co., Ltd. has approved a grant of 6,130,000 existing H shares, equal to 1.55% of its issued share capital (excluding treasury shares), to 51 employees under its previously adopted share award scheme, including four directors and three supervisors of significant subsidiaries. The awards, sourced entirely from H shares purchased on the market by a trustee, will vest by November 30, 2026 subject to individual performance targets, differentiated vesting prices for two employee categories, and a clawback mechanism allowing the company to forfeit vested shares or related benefits if grantees damage the company’s core interests or cause legal, economic, or reputational harm, thereby aligning management and staff incentives more closely with shareholder value without diluting existing share capital.
The most recent analyst rating on (HK:2522) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. announced that shareholders approved a special resolution at an extraordinary general meeting held online on 13 January 2026, with about 40.46% of the company’s issued share capital (excluding treasury shares) represented. The resolution to dissolve the Board of Supervisors and amend the Articles of Association and its appendices passed with over two-thirds of votes in favour, meaning the company will no longer maintain a supervisory board and its current supervisors have ceased to hold office as of the meeting date, marking a significant governance structure change that aligns its constitutional documents with the new oversight framework.
The most recent analyst rating on (HK:2522) stock is a Sell with a HK$9.50 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd., a PRC-incorporated joint stock company listed in Hong Kong, operates under a standard board governance framework with executive, non-executive and independent non-executive directors in line with local listing rules. The company has called an extraordinary general meeting for 13 January 2026, to be held virtually, where shareholders will vote on a special resolution to dissolve the Board of Supervisors and amend the Articles of Association and related appendices, a move that would reshape its governance structure and centralise oversight responsibilities within the existing board; the meeting will be conducted by poll, with detailed arrangements for online attendance, proxy voting, and shareholder qualification periods set out to ensure broad participation from both registered and non-registered holders of H shares.
The most recent analyst rating on (HK:2522) stock is a Sell with a HK$14.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd., a PRC-incorporated joint stock company listed in Hong Kong under stock code 2522, is governed by a board comprising executive, non-executive and independent non-executive directors in line with Hong Kong capital market requirements. The company has scheduled an extraordinary general meeting for 13 January 2026 and will close its register of members from 8 to 13 January 2026 to determine shareholders entitled to attend and vote, with share transfer documents due by 7 January; the meeting will consider the proposed dissolution of the board of supervisors and amendments to the articles of association and related procedural rules, signaling a potential overhaul of its governance framework that could reshape internal oversight and shareholder participation in corporate decision-making.
The most recent analyst rating on (HK:2522) stock is a Sell with a HK$14.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. announced a connected transaction involving a joint and several liability guarantee for a credit facility of up to RMB50 million with XW Bank, in collaboration with Shanghai Ronggongshe. This agreement, which involves Rimag Yuntai and Wuhan Ronggongshe, is subject to specific reporting requirements under the Hong Kong Stock Exchange Listing Rules, reflecting the company’s strategic financial maneuvers to support its subsidiaries and enhance its market positioning in the medical imaging industry.
The most recent analyst rating on (HK:2522) stock is a Sell with a HK$14.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. has announced a share repurchase under its repurchase mandate, acquiring 194,000 H Shares at an average price of approximately HK$10.2868 per share. This move is part of a broader strategy to reflect the intrinsic value of the shares and demonstrate management’s confidence in the company’s long-term prospects. Additionally, the company’s Chairman, Mr. Chen Zhaoyang, has increased his shareholding by purchasing 58,000 H Shares, further signaling confidence in the company’s growth potential. These actions are intended to promote stable development and safeguard public investor interests while maintaining sufficient public float.
The most recent analyst rating on (HK:2522) stock is a Sell with a HK$14.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. announced that its chairman, executive director, and CEO, Mr. Chen Zhaoyang, has increased his shareholding in the company by purchasing an additional 55,000 H shares. This move, reflecting confidence in the company’s growth prospects, represents approximately 0.01% of the total issued shares and brings Mr. Chen’s total interest to about 14.49% of the company’s shares. The company assures that it maintains a sufficient public float of its issued shares following this transaction.
The most recent analyst rating on (HK:2522) stock is a Sell with a HK$14.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. has announced significant changes to its corporate governance structure, including adjustments to the composition of its board committees and the dissolution of its Board of Supervisors. These changes are in response to amendments in the Hong Kong Stock Exchange’s listing rules and aim to enhance corporate governance by transferring the supervisory board’s functions to the audit committee. The amendments to the Articles of Association will be effective upon approval by the company’s general meeting.
The most recent analyst rating on (HK:2522) stock is a Sell with a HK$14.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. has established a nomination committee to identify and recommend suitable candidates for its board of directors, ensuring compliance with applicable laws and regulations. The committee will also oversee board performance evaluations and develop nomination guidelines. The committee will consist of at least three members, with a majority being independent non-executive directors, and will meet at least once a year to fulfill its responsibilities.
The most recent analyst rating on (HK:2522) stock is a Sell with a HK$14.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. has established a remuneration committee to oversee the compensation policies for its directors and senior management. The committee is tasked with recommending remuneration packages, evaluating performance, and ensuring transparency in the development of remuneration policies. This move is aimed at strengthening the governance structure of the company and aligning management incentives with shareholder interests.
The most recent analyst rating on (HK:2522) stock is a Sell with a HK$14.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. has established an audit committee to assist and advise its board of directors in financial reporting, risk management, and maintaining relationships with auditors. The committee will ensure compliance with the Company Law of the People’s Republic of China and the Listing Rules of the Hong Kong Stock Exchange. The committee will consist of at least three non-executive directors, with a majority being independent, and will meet at least twice annually to discuss financial matters and connected transactions.
The most recent analyst rating on (HK:2522) stock is a Sell with a HK$14.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. announced that its Chairman, Executive Director, and CEO, Mr. Chen Zhaoyang, has increased his shareholding in the company by purchasing 59,500 H shares in the open market. This move, reflecting confidence in the company’s growth potential, aims to promote its stable development and protect public investors’ interests. Following this transaction, Mr. Chen now holds approximately 14.48% of the company’s total issued shares. The company assures that it maintains a sufficient public float of its issued shares.
The most recent analyst rating on (HK:2522) stock is a Sell with a HK$14.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. has announced its intention to further repurchase H shares on the open market, with a potential value of up to HK$200 million, under a general mandate approved by its shareholders. This move is seen as a demonstration of the company’s confidence in its business prospects and is expected to benefit both the company and its shareholders. The repurchase will be conducted in compliance with relevant laws and regulations, and the repurchased shares may be canceled, held in treasury, or transferred as deemed appropriate by the board.
The most recent analyst rating on (HK:2522) stock is a Sell with a HK$14.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. has entered into a strategic cooperation agreement with the Qingyang Government and Medical Image Insights to establish shared medical imaging centers and digital platforms. This collaboration aims to improve regional medical resource integration, expand market presence in Northwest China, and enhance the efficiency of medical data utilization, benefiting the company’s operations and stakeholders.
The most recent analyst rating on (HK:2522) stock is a Hold with a HK$16.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. has announced the repurchase of 1,775,000 H Shares in the market over the past six months, amounting to approximately HK$29,176,640. The repurchased shares will be held as treasury shares and are intended for use in employee incentives, sale, or transfer. The company believes this move will enhance share value and benefit shareholders, while maintaining sufficient public float as per listing requirements. The board remains optimistic about the company’s future development prospects.
The most recent analyst rating on (HK:2522) stock is a Hold with a HK$16.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. announced that certain directors have increased their shareholding in the company, purchasing a total of 96,500 H shares. This decision reflects their confidence in the company’s recent achievements and strategic alignment with national policies on AI and healthcare, suggesting that the current share price undervalues the company’s long-term potential.
The most recent analyst rating on (HK:2522) stock is a Hold with a HK$16.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. has announced a strategic collaboration with Beijing Rimag Sunshine Medical Information Technology Co Ltd., Beijing Data Pioneer Zone Service Co., Ltd., and Beijing International Computing Power Service Co., Ltd. to establish a high-quality medical imaging database. This partnership, leveraging the Beijing Artificial Intelligence Data Sandbox, aims to transform the company’s data assets into marketable products, marking a significant breakthrough with the successful execution of a RMB10 million contract. The initiative aligns with national policies on data element marketization and is expected to bolster the company’s business development and competitive edge in the AI-based medical imaging sector.
The most recent analyst rating on (HK:2522) stock is a Hold with a HK$16.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
Jiangxi Rimag Group Co., Ltd. has announced a capital increase in Shanghai Medical Image Insights Intelligent Technology Co., Ltd., investing approximately RMB100 million to enhance its shareholding. This strategic investment aligns with Jiangxi Rimag’s long-term plan to deepen its presence in the medical imaging field, leveraging AI technology to improve service quality and competitiveness. The move is expected to strengthen the company’s position in the rapidly growing imaging AI market, improve diagnostic capabilities, and consolidate its leadership in China’s medical imaging AI sector.
The most recent analyst rating on (HK:2522) stock is a Hold with a HK$16.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.